ᱡᱚᱱᱥᱚᱱ ᱮᱱᱰ ᱡᱚᱱᱥᱚᱱ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱯᱷᱮᱰᱟᱛ ᱧᱮᱞᱢᱮ

ᱟᱢᱟᱜ ᱱᱚᱭᱟ ᱥᱟᱦᱴᱟ ᱥᱟᱯᱲᱟᱣᱢᱮ ᱠᱟᱹᱢᱤᱨᱮ ᱟᱹᱭᱫᱟᱹᱨᱤ ᱫᱚ ᱵᱟᱱᱩᱜ-ᱟ, ᱚᱱᱟ ᱨᱮᱭᱟᱜ :

Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis.

The block was made by ‪EPIC‬. The reason given is Open proxy/Webhost: See the help page if you are affected.

Start of block: ᱐᱘:᱔᱘, ᱒ ᱡᱩᱞᱟᱭ ᱒᱐᱒᱔
Expiry of block: ᱐᱘:᱔᱘, ᱒ ᱡᱩᱞᱟᱭ ᱒᱐᱒᱕

Your current IP address is 206.189.44.186. The blocked range is 206.189.32.0/20.

Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy.

Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

ᱱᱚᱭᱟ ᱥᱟᱦᱴᱟᱢ ᱧᱮᱞ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱟᱨᱮᱢ ᱠᱚᱯᱤ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ᱾

{{Infobox drug
| Verifiedfields     =
| verifiedrevid      =
| drug_name          =
| INN                =
| type               = vaccine
| image              =Janssen COVID-19 vaccine (2021) F (cropped).jpg
| alt                =
| caption            = A vial of Janssen COVID-19 Vaccine

<!-- Vaccine data -->
| target             = [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
| vaccine_type       = viral

<!-- Clinical data -->
| pronounce          =
| tradename          = Janssen COVID-19<ref>{{cite web | title=Janssen COVID-19 Emergency Use Authorization (EUA) Official Website | website=Janssen | date=28 February 2021 | url=https://www.janssencovid19vaccine.com/hcp.html | access-date=28 February 2021 | archive-date=1 March 2021 | archive-url=https://web.archive.org/web/20210301040436/https://www.janssencovid19vaccine.com/hcp.html }}</ref> 
| Drugs.com          = {{drugs.com|mtm|janssen-covid-19-vaccine-pf}}
| MedlinePlus        =
| licence_EU         = yes
| DailyMedID         = Janssen_COVID-19_Vaccine
| licence_US         = 
| pregnancy_AU       = B1
| pregnancy_AU_comment = <ref name="COVID-19 Vaccine Janssen APM summary">{{cite web | title=COVID-19 Vaccine Janssen | website=Therapeutic Goods Administration (TGA) | date=25 June 2021 | url=https://www.tga.gov.au/apm-summary/covid-19-vaccine-janssen | access-date=28 August 2021 | archive-date=28 August 2021 | archive-url=https://web.archive.org/web/20210828190300/https://www.tga.gov.au/apm-summary/covid-19-vaccine-janssen | url-status=dead }}</ref>
| pregnancy_category =
| routes_of_administration = [[Intramuscular injection|Intramuscular]]
| class              =
| ATCvet             =
| ATC_prefix         = None <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix         =
| ATC_supplemental   =

<!-- Legal status -->
| legal_AU           = S4
| legal_AU_comment   =<ref>{{Cite web |url=https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=3FBA16FEFCEB4AFBCA2586FF00421EDC&agid=(PrintDetailsPublic)&actionid=1 |title=Archive copy |access-date=2021-09-20 |archive-date=2021-08-28 |archive-url=https://web.archive.org/web/20210828190324/https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs%2FPublicHTML%2FpdfStore.nsf&docid=3FBA16FEFCEB4AFBCA2586FF00421EDC&agid=%28PrintDetailsPublic%29&actionid=1 |url-status=dead }}</ref>
| legal_BR           = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment   =
| legal_CA           = Schedule D; Authorized by interim order
| legal_CA_comment   = <ref name="CA authorization">{{cite web | title=Regulatory Decision Summary – Janssen COVID-19 Vaccine – Health Canada | website=[[Health Canada]] | date=5 March 2021 | url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00779 | access-date=5 March 2021 | archive-date=5 March 2021 | archive-url=https://web.archive.org/web/20210305154318/https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00779}}</ref><ref>{{cite web | title=Janssen COVID-19 Vaccine monograph | publisher=Janssen | url=https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf | date=5 March 2021 | access-date=5 March 2021 | archive-date=5 March 2021 | archive-url=https://web.archive.org/web/20210305152243/https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf }}</ref>
| legal_DE           = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment   =
| legal_NZ           = <!-- Class A, B, C -->
| legal_NZ_comment   =
| legal_UK           = Conditional marketing authorization granted
| legal_UK_comment   = <ref name="UK approval">{{cite web | title=Regulatory approval of COVID-19 Vaccine Janssen | publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) | date=28 May 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen | access-date=29 May 2021 | archive-date=28 May 2021 | archive-url=https://web.archive.org/web/20210528203520/https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen }}</ref><ref name="UK PR">{{cite press release | title=One-dose Janssen COVID-19 vaccine approved by the MHRA | publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) | date=28 May 2021 | url=https://www.gov.uk/government/news/one-dose-janssen-covid-19-vaccine-approved-by-the-mhra | access-date=29 May 2021 | archive-date=28 May 2021 | archive-url=https://web.archive.org/web/20210528193415/https://www.gov.uk/government/news/one-dose-janssen-covid-19-vaccine-approved-by-the-mhra }}</ref><ref name="COVID-19 Vaccine Janssen SmPC">{{cite web | title=Summary of Product Characteristics for COVID-19 Vaccine Janssen | publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) | date=28 May 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen/summary-of-product-characteristics-for-covid-19-vaccine-janssen | access-date=29 May 2021 | archive-date=28 May 2021 | archive-url=https://web.archive.org/web/20210528203627/https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen/summary-of-product-characteristics-for-covid-19-vaccine-janssen}}</ref>
| legal_US           = Standing Order; Unapproved
| legal_US_comment   = <ref name="FDA PR 20210227">{{cite press release |title=FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine |website=U.S. [[Food and Drug Administration]] (FDA) |date=27 February 2021 |url=https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine |access-date=27 February 2021 |archive-date=18 March 2021 |archive-url=https://web.archive.org/web/20210318174827/https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine}}</ref><ref name="FDA EUA">{{cite web | url=https://www.fda.gov/media/146303/download | format=PDF | title=FDA Letter of Authorization | quote=...letter is in response to a request from Janssen Biotech, Inc. that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA)... | date=27 February 2021 | access-date=28 February 2021 | archive-date=10 March 2021 | archive-url=https://web.archive.org/web/20210310103959/https://www.fda.gov/media/146303/download }}</ref><ref name="CDC standing order">{{cite web | url=https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Standing-Orders.pdf | title=Janssen COVID-19 Vaccine (Johnson & Johnson) Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older | publisher=U.S. [[Centers for Disease Control and Prevention]] (CDC) | access-date=16 April 2021 | archive-date=16 April 2021 | archive-url=https://web.archive.org/web/20210416214154/https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Standing-Orders.pdf }}</ref>
| legal_EU           = Conditional marketing authorization granted
| legal_EU_comment   = <ref name="COVID-19 Vaccine Janssen EPAR">{{cite web |title=COVID-19 Vaccine Janssen EPAR |url=https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen |publisher=[[European Medicines Agency]] (EMA) |date=5 March 2021 |access-date=16 March 2021 |archive-date=15 March 2021 |archive-url=https://web.archive.org/web/20210315172052/https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment   =
| legal_status       = <!-- For countries not listed above -->
ZA: Authorized<ref>{{Cite web|title=Johnson & Johnson Covid vaccine approved for general use in South Africa|url=https://businesstech.co.za/news/government/480685/johnson-johnson-covid-vaccine-approved-for-general-use-in-south-africa/|access-date=9 May 2021|archive-date=9 May 2021|archive-url=https://web.archive.org/web/20210509154036/https://businesstech.co.za/news/government/480685/johnson-johnson-covid-vaccine-approved-for-general-use-in-south-africa/}}</ref><ref>{{Cite news|date=1 April 2021|title=J&J Covid-19 Vaccine Approved in South Africa for Wider Use|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2021-04-01/j-j-covid-19-vaccine-approved-in-south-africa-for-general-use|access-date=9 May 2021|archive-date=9 April 2021|archive-url=https://web.archive.org/web/20210409182933/https://www.bloomberg.com/news/articles/2021-04-01/j-j-covid-19-vaccine-approved-in-south-africa-for-general-use}}</ref>

<!-- Identifiers -->
| CAS_number         =
| CAS_supplemental   =
| PubChem            =
| IUPHAR_ligand      =
| DrugBank           = DB15857
| ChemSpiderID       =
| UNII               = JT2NS6183B
| KEGG               = D12129
| ChEBI_Ref          =
| ChEBI              =
| ChEMBL_Ref         =
| ChEMBL             =
| NIAID_ChemDB       =
| PDB_ligand         =
| synonyms           = {{ubl|
  | Ad26.COV2.S
  | VAC31518<ref name="J&J Protocol">{{cite web |title=A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE Protocol VAC31518COV3001; Phase 3 |url=https://www.jnj.com/coronavirus/ensemble-1-study-protocol |format=PDF |publisher=[[Janssen Pharmaceutica|Janssen Vaccines & Prevention]] |access-date=15 February 2021 |archive-date=18 February 2021 |archive-url=https://web.archive.org/web/20210218014735/https://www.jnj.com/coronavirus/ensemble-1-study-protocol  }}</ref><ref name="J&J ENSEMBLE 2 Protocol">{{cite web | url=https://www.jnj.com/coronavirus/ensemble-2-study-protocol | format=PDF | title=A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE 2 Protocol VAC31518COV3009; Phase 3 | publisher=[[Janssen Pharmaceutica|Janssen Vaccines & Prevention]] | access-date=26 February 2021 | archive-date=25 February 2021 | archive-url=https://web.archive.org/web/20210225195720/https://www.jnj.com/coronavirus/ensemble-2-study-protocol  }}</ref>
 }}

<!-- Chemical and physical data -->
}}
'''ᱡᱚᱱᱥᱚᱱ ᱮᱱᱰ ᱡᱚᱱᱥᱚᱱ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ''' ᱫᱚ ᱱᱮᱫᱟᱨᱞᱮᱱᱰᱥ ᱨᱮᱱᱟᱜ ᱞᱟᱭᱰᱮᱱ ᱡᱮᱱᱥᱮᱱ ᱵᱷᱮᱠᱥᱤᱱᱥ ᱟᱨ ᱵᱮᱞᱡᱤᱭᱟᱢ ᱨᱮᱱᱟᱜ ᱡᱮᱱᱥᱮᱱ ᱯᱷᱟᱨᱢᱟᱥᱤᱣᱴᱤᱠᱮᱞᱥ, ᱟᱢᱮᱨᱤᱠᱟᱱ ᱜᱚᱸᱲᱚ ᱥᱚᱯᱚ ᱡᱚᱱᱥᱚᱱ ᱮᱱᱰ ᱡᱚᱱᱥᱚᱱ ᱟᱜ ᱵᱮᱱᱟᱣ ᱟᱠᱟᱱ ᱢᱤᱫᱴᱮᱱ [[ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ]] ᱠᱟᱱᱟ ᱾ 

ᱱᱚᱣᱟ ᱫᱚ ᱦᱚᱲᱟᱜ ᱮᱰᱤᱱᱳᱵᱷᱟᱭᱨᱟᱥ ᱥᱮᱞᱮᱫ ᱢᱤᱫᱴᱮᱱ ᱵᱷᱟᱭᱨᱟᱞ ᱵᱷᱮᱠᱴᱚR ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ ᱡᱟᱸᱦᱟᱸ ᱫᱚ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱠᱷᱟᱹᱛᱤᱨ ᱮᱥ ᱮ ᱟᱨ ᱮᱥ-ᱠᱳᱵᱷᱤ-᱒ ᱵᱷᱟᱭᱨᱟᱥ ᱨᱮᱱᱟᱜ ᱮᱥᱯᱟᱭᱤᱠ ᱯᱨᱳᱴᱤᱱ ᱵᱮᱱᱟᱣ ᱫᱟᱨᱟᱭᱛᱮ ᱦᱚᱲᱢᱚ ᱨᱮᱱᱟᱜ ᱡᱤᱱ ᱨᱮᱱᱟᱜ ᱵᱚᱫᱞᱟᱣ ᱮ ᱟᱹᱜᱩᱭᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱫᱚ ᱢᱤᱫᱴᱮᱱ ᱰᱳᱡᱽ ᱜᱮ ᱞᱟᱜᱟᱜᱼᱟ ᱟᱨ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱫᱚ ᱨᱮᱭᱟᱲ ᱡᱟᱜᱟ ᱨᱮ  ᱫᱚᱦᱚ ᱦᱚᱸ ᱵᱟᱝ ᱞᱟᱜᱟᱜᱼᱟ᱾

᱒᱐᱒᱐ ᱥᱮᱨᱢᱟ ᱨᱮᱱᱟᱜ ᱡᱩᱱ ᱪᱟᱸᱫᱚ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱮᱛᱦᱟᱵ ᱟᱠᱟᱱᱟ᱾ ᱡᱚᱱᱥᱚᱱ ᱮᱱᱰ ᱡᱚᱱᱥᱚᱱ ᱮ ᱢᱮᱱ ᱟᱠᱟᱫᱟ ᱡᱮ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱮᱢ ᱒᱘ ᱢᱟᱦᱟᱸ ᱛᱟᱭᱚᱢ ᱦᱚᱲᱢᱚᱨᱮ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱮᱱᱴᱤᱵᱚᱰᱤ ᱛᱮᱭᱟᱨᱚᱜᱼᱟ᱾ 

ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱫᱚ ᱢᱟᱨᱠᱤᱱ ᱡᱚᱢ ᱟᱨ ᱨᱟᱱ ᱵᱤᱵᱷᱟᱜᱽ ᱠᱷᱚᱱ ᱡᱟᱹᱨᱩᱲ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱛ ᱤᱣᱨᱳᱯᱤᱭᱟᱱ ᱢᱮᱰᱤᱥᱤᱱ ᱮᱡᱮᱱᱥᱤ ᱫᱟᱨᱟᱭᱛᱮ ᱠᱤᱪᱷᱩᱜᱟᱱ ᱥᱚᱨᱛᱚ ᱞᱮᱠᱟᱛᱮ ᱵᱟᱡᱟᱨᱡᱟᱛ ᱨᱮᱱᱟᱜ ᱟᱹᱭᱫᱟᱹᱨᱤᱭ ᱧᱟᱢ ᱟᱠᱟᱫᱟ᱾

== ᱥᱟ.ᱠᱷᱭᱟ.ᱛ==
{{ᱥᱟ.ᱠᱷᱭᱟ.ᱛ}}
[[ᱛᱷᱚᱠ:ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ]]

ᱱᱚᱶᱟ ᱥᱟᱦᱴᱟᱨᱮ ᱵᱮᱵᱷᱟᱨᱟᱠᱟᱱ ᱪᱷᱟᱸᱪᱠᱚ :

ᱡᱚᱱᱥᱚᱱ ᱮᱱᱰ ᱡᱚᱱᱥᱚᱱ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱛᱮ ᱨᱩᱭᱟᱹᱲᱚᱜ ᱢᱮ

"https://sat.wikipedia.org/wiki/ᱡᱚᱱᱥᱚᱱ_ᱮᱱᱰ_ᱡᱚᱱᱥᱚᱱ_ᱠᱳᱵᱷᱤᱰ-᱑᱙_ᱴᱤᱠᱟᱹ" ᱠᱷᱚᱱ ᱧᱟᱢ ᱟᱹᱜᱩᱭ